Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation

Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucos...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-09, Vol.16 (9), p.1125
Main Authors: Mikhel, Iosif B, Bakhrushina, Elena O, Petrusevich, Danila A, Nedorubov, Andrey A, Appolonova, Svetlana A, Moskaleva, Natalia E, Demina, Natalia B, Kosenkova, Svetlana I, Parshenkov, Mikhail A, Krasnyuk, Jr, Ivan I, Krasnyuk, Ivan I
Format: Article
Language:English
Subjects:
Animal experimentation
anticancer therapy
Bioavailability
Brain cancer
Brain tumors
cancer
Cancer therapies
Drug development
Drug dosages
Foreign bodies
in situ systems
Instrument industry
intranasal administration
Nose
nose-to-brain mechanism
Phase transitions
Polymers
Polysaccharides
Ribavirin
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16091125